Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): A randomised non-inferiority trial

The Lancet

Volumn 385, Issue 9977, 2015, Pages 1527-1535

  Raungaard, Bent ^a   Jensen, Lisette Okkels ^a   Tilsted, Hans Henrik ^a   Christiansen, Evald Høj ^c   Maeng, Michael ^c   Terkelsen, Christian Juhl ^c   Krusell, Lars Romer ^c   Kaltoft, Anne ^c   Kristensen, Steen Dalby ^c   Bøtker, Hans Erik ^c   Thuesen, Leif ^c   Aarøe, Jens ^a   Jensen, Svend Eggert ^a,b   Villadsen, Anton Boel ^a   Thayssen, Per ^b   Veien, Karsten Tange ^b   Hansen, Knud Nørregaard ^b   Junker, Anders ^b   Madsen, Morten ^c   Ravkilde, Jan ^a   Lassen, Jens Flensted ^c   more..

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMER; UMIROLIMUS; ZOTAROLIMUS; BIOMATERIAL; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; BIOLIMUS ELUTING BIODEGRADABLE POLYMER COATED STENT; BIOLIMUS ELUTING CORONARY STENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEVICE SAFETY; DRUG EFFICACY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION; ZOTAROLIMUS ELUTING CORONARY STENT; ZOTAROLIMUS ELUTING DURABLE POLYMER COATED STENT; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; COMPARATIVE STUDY; DENMARK; DRUG ELUTING STENT; EQUIPMENT DESIGN; MIDDLE AGED; MORTALITY; MYOCARDIAL ISCHEMIA; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; COATED MATERIALS, BIOCOMPATIBLE; DENMARK; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84928421053     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61794-3     Document Type: Article

References (41)

1. MC Morice, PW Serruys, JE Sousa et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. JW Moses, MB Leon, JJ Popma et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
3. GW Stone, SG Ellis, DA Cox et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
4. J Daemen, P Wenaweser, K Tsuchida et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
5. LO Jensen, HH Tilsted, P Thayssen et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry EuroIntervention 5 2010 898 905
6. M Joner, AV Finn, A Farb et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
7. R Virmani, G Guagliumi, A Farb et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 2004 701 705
8. K Rasmussen, M Maeng, A Kaltoft et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
9. E Kedhi, KS Joesoef, E McFadden et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
10. GW Stone, M Midei, W Newman et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913
11. LO Jensen, P Thayssen, HS Hansen et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV) Circulation 125 2012 1246 1255
12. PW Serruys, S Silber, S Garg et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
13. GP Talarico, F Burzotta, C Trani et al. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents, the impact of polymer coating in DES technology Catheter Cardiovasc Interv 81 2013 268 273
14. C von Birgelen, H Sen, MK Lam et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial Lancet 383 2013 413 423
15. RA Byrne, A Kastrati, S Massberg et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial J Am Coll Cardiol 58 2011 1325 1331
16. PC Smits, S Hofma, M Togni et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial Lancet 381 2013 651 660
17. EH Christiansen, LO Jensen, P Thayssen et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial Lancet 381 2013 661 669
18. S Windecker, PW Serruys, S Wandel et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
19. JY Lee, DW Park, YH Kim et al. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions. A randomized long drug-eluting stent V trial Circ Cardiovasc Interv 7 2014 322 329
20. Q Zhang, JP Qiu, AJ Kirtane et al. Comparison of biodegradable polymer versus durable polymer sirolimus-eluting stenting in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the RESOLVE study J Interv Cardiol 27 2014 131 141
21. T Pilgrim, D Heg, M Roffi et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): A randomised, single-blind, non-inferiority trial Lancet 2014 published online Sept 1. http://dx.doi.org/10.1016/S0140-6736(14)61038-2
22. SH Kang, KW Park, DY Kang et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J 35 2014 1147 1158
23. S Bangalore, B Toklu, N Amoroso et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis BMJ 347 2013 f6625
24. EP Navarese, K Tandjung, B Claessen et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis BMJ 347 2013 f6530
25. T Palmerini, G Biondi-Zoccai, D Della Riva et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis J Am Coll Cardiol 63 2014 299 307
26. K Thygesen, JS Alpert, HD White Universal definition of myocardial infarction Eur Heart J 28 2007 2525 2538
27. DE Cutlip, S Windecker, R Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
28. L Thuesen, LO Jensen, HH Tilsted et al. Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology Clin Epidemiol 5 2013 357 361
29. KW Park, JM Lee, SH Kang et al. Everolimus-eluting xience v/promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus JACC Cardiovasc Interv 7 2014 471 481
30. XT Li, H Sun, DP Zhang et al. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents Coron Artery Dis 25 2014 405 411
31. R Caputo, M Leon, P Serruys et al. Performance of the resolute zotarolimus-eluting stent in small vessels Catheter Cardiovasc Interv 84 2014 17 23
32. K Teeuwen, BJ Van den Branden, JJ Koolen et al. Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions EuroIntervention 2014 published online Aug 20. http://dx.doi.org/doi: 10.4244/EIJY14M08-07
33. E Camenzind, W Wijns, L Mauri et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 2012 1396 1405
34. MB Leon, DE Kandzari, EL Eisenstein ENDEAVOR IV Investigators Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (randomized, controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Taxus paclitaxel-eluting coronary stent system in de novo native coronary artery lesions) JACC Cardiovasc Interv 2 2009 1208 1218
35. L Raber, H Kelbaek, M Ostojic et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial JAMA 308 2012 777 787
36. GG Stefanini, RA Byrne, PW Serruys et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials Eur Heart J 33 2012 1214 1222
37. K Kolandaivelu, R Swaminathan, WJ Gibson et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings Circulation 123 2011 1400 1409
38. JM Lee, SD Park, SY Lim et al. Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial Trials 14 2013 398
39. MK Lam, H Sen, K Tandjung et al. Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial Am Heart J 167 2014 445 451
40. PW Serruys, V Farooq, B Kalesan et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer- based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial JACC Cardiovasc Interv 6 2013 777 789
41. M Maeng, HH Tilsted, LO Jensen et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial Lancet 383 2014 2047 2056